RxDoctor Payments Data

Benjamin Bert, MD

Ophthalmology · Fountain Valley, CANPI 1518129964

Payments from drug & device makers

$128,260in general payments, 2019–2025

Across 123 payments — averaging $1042.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$92K
  • Bausch & Lomb Americas Inc.$24K
  • Regeneron$10K
  • Sun Pharmaceutical Industries Inc.$491
  • Alcon$480
  • Merz Pharmaceuticals, LLC$285
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$2,673100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$128,260 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$395,332
Medicare patients
1,068
Services billed
2,533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine118$94,038
XiidraLifitegrast78$77,392
MieboPerfluorohexyloctane/Pf76$66,528
Cyclosporine65$25,285
CequaCyclosporine28$18,813
TyrvayaVarenicline Tartrate23$18,526
Prednisolone Acetate484$16,571
LumiganBimatoprost36$15,002
CombiganBrimonidine Tartrate/Timolol14$8,981
MoxifloxacinMoxifloxacin Hcl365$7,701
Loteprednol Etabonate36$4,950
Ketorolac Tromethamine263$3,791
SimbrinzaBrinzolamide/Brimonidine Tart12$3,452
ValacyclovirValacyclovir Hcl39$2,992
Brimonidine Tartrate41$2,889

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo$23,771$143,920154 claims
Sun Pharmaceutical Industries Inc.Cequa$491$18,81328 claims
Oyster Point Pharma, Inc.Tyrvaya$165$18,52623 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$195$4,95036 claims
AlconSimbrinza$480$3,45212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Fountain Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →